Sintx Technologies
Market Cap
US$4.3m
Last Updated
2020/01/25 00:31 UTC
Data Sources
Company Financials +
Executive Summary
Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America.
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Sintx Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SINT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.3%
SINT
-0.4%
US Medical Equipment
-1.3%
US Market
1 Year Return
-73.1%
SINT
27.3%
US Medical Equipment
22.0%
US Market
Return vs Industry: SINT underperformed the US Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: SINT underperformed the US Market which returned 24.7% over the past year.
Shareholder returns
| SINT | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.3% | -0.4% | -1.3% |
| 30 Day | 14.1% | 2.8% | 1.8% |
| 90 Day | -29.5% | 11.8% | 9.3% |
| 1 Year | -73.1%-73.1% | 28.3%27.3% | 24.6%22.0% |
| 3 Year | -98.9%-98.9% | 91.8%86.3% | 49.2%39.6% |
| 5 Year | -100.0%-100.0% | 131.2%106.5% | 77.9%58.3% |
Price Volatility Vs. Market
How volatile is Sintx Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Companies Like Sintx Technologies (NASDAQ:SINT) Can Be Considered Quite Risky2 months ago | Simply Wall St
Can We See Significant Insider Ownership On The Sintx Technologies, Inc. (NASDAQ:SINT) Share Register?Valuation
Is Sintx Technologies undervalued compared to its fair value and its price relative to the market?
0.66x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SINT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SINT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SINT is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: SINT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SINT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SINT is good value based on its PB Ratio (0.7x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Sintx Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
9.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SINT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SINT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SINT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SINT's revenue (84.1% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: SINT's revenue (84.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SINT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Sintx Technologies performed over the past 5 years?
16.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SINT is currently unprofitable.
Growing Profit Margin: SINT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SINT is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare SINT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SINT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).
Return on Equity
High ROE: SINT has a negative Return on Equity (-80.62%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Sintx Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: SINT's short term assets ($4.9M) exceed its short term liabilities ($2.1M).
Long Term Liabilities: SINT's short term assets ($4.9M) exceed its long term liabilities ($2.5M).
Debt to Equity History and Analysis
Debt Level: SINT's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: SINT's debt to equity ratio has reduced from 190.7% to 0.3% over the past 5 years.
Balance Sheet
Inventory Level: SINT has a high level of physical assets or inventory.
Debt Coverage by Assets: SINT's debt is covered by short term assets (assets are 231.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SINT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SINT has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.5% each year.
Next Steps
Dividend
What is Sintx Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SINT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SINT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SINT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SINT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SINT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Sintx Technologies's salary, the management and board of directors tenure and is there insider trading?
4.7yrs
Average management tenure
CEO
B. Bal (57yo)
5.3yrs
Tenure
US$401,231
Compensation
Dr. B. Sonny Bal, M.D., J.D., MBA, PhD, has been the Chief Executive Officer and President of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since October 2014 and its Chairman since Augu ...
CEO Compensation Analysis
Compensation vs Market: B.'s total compensation ($USD401.23K) is about average for companies of similar size in the US market ($USD519.76K).
Compensation vs Earnings: B.'s compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.7yrs
Average Tenure
57yo
Average Age
Experienced Management: SINT's management team is considered experienced (4.7 years average tenure).
Board Age and Tenure
5.4yrs
Average Tenure
59.5yo
Average Age
Experienced Board: SINT's board of directors are considered experienced (5.4 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 442.5%.
Management Team
Bryan McEntire (67yo)
Chief Scientific Officer
- Tenure: 2yrs
- Compensation: US$249.31k
B. Bal (57yo)
Chairman
- Tenure: 5.3yrs
- Compensation: US$401.23k
David O'brien (54yo)
Chief Operating Officer
- Tenure: 4.7yrs
Board Members
Dave Truetzel (62yo)
Independent Director
- Tenure: 9.3yrs
- Compensation: US$122.00k
Eric Stookey (49yo)
Independent Director
- Tenure: 5.3yrs
- Compensation: US$42.00k
B. Bal (57yo)
Chairman
- Tenure: 5.3yrs
- Compensation: US$401.23k
Jeff White (65yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$42.00k
Giuseppe Pezzotti
Member of Scientific Advisory Board
- Tenure: 4.3yrs
Company Information
Sintx Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sintx Technologies, Inc.
- Ticker: SINT
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$4.333m
- Shares outstanding: 2.43m
- Website: https://www.sintx.com
Number of Employees
Location
- Sintx Technologies, Inc.
- 1885 West 2100 South
- Salt Lake City
- Utah
- 84119
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SINT | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Feb 2014 |
| 111N | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. Sintx Technologies, Inc. has a collaboration agreement with CTL Amedica to design and launch spinal implants. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/25 00:31 |
| End of Day Share Price | 2020/01/24 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.